Zhou Changlin, Yang Chunsheng, Chong Daoqun
Department of Oncology, Jining No.1 People's Hospital, Jining, China.
Medicine (Baltimore). 2019 Jul;98(30):e16187. doi: 10.1097/MD.0000000000016187.
Recently, many studies have been carried out to investigate the clinicopathological significance of E-cadherin expression in thyroid cancer. However, the results remained inconsistent. In the present study, we performed a meta-analysis to evaluate the associations of E-cadherin expression with susceptibility and clinicopathological characteristics of thyroid cancer.
Eligible studies were searched from Medicine, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The strength of associations between E-cadherin expression and susceptibility and clinicopathological features of thyroid cancer were assessed by pooled odds ratios (ORs) and 95% confidence intervals (CIs).
Forty-six studies with 1700 controls and 2298 thyroid cancer patients were included for this meta-analysis. Pooled results indicated that E-cadherin expression was significantly associated with susceptibility of papillary cancer and follicular cancer (papillary cancer, ORs = 14.31, 95% CIs = 3.42-59.90; follicular cancer, ORs = 10.14, 95% CI = 4.52-22.75). Significant association between E-cadherin expression and thyroid cancer risk was also observed in the subgroup analysis based on control group (normal thyroid tissue, ORs = 28.28, 95% CI = 8.36-95.63; adjacent thyroid tissue, ORs = 8.83, 95% CI = 3.27-23.85; benign thyroid tissue, ORs = 43.96, 95% CI = 9.91-194.95). In addition, E-cadherin expression was significantly correlated with lymph node metastasis, differentiation, and tumor-node-metastasis (TNM) stage of thyroid cancer (lymph node metastasis, ORs = 3.21, 95% CI = 1.98-5.20; differentiation, ORs = 0.25, 95% CI = 0.07-0.82; TNM stage, ORs = 4.85, 95% CI = 2.86-8.25).
The present study showed that E-cadherin expression was significantly associated with susceptibility and clinicopathological characteristics of thyroid cancer, which suggested that E-cadherin expression might be a potential predictive factor for clinical progression of thyroid cancer.
近年来，许多研究探讨了E-钙黏蛋白表达在甲状腺癌中的临床病理意义。然而，结果仍不一致。在本研究中，我们进行了一项荟萃分析，以评估E-钙黏蛋白表达与甲状腺癌易感性及临床病理特征之间的关联。
从医学、Embase、科学网、中国知网和万方数据库中检索符合条件的研究。通过合并比值比（OR）和95%置信区间（CI）评估E-钙黏蛋白表达与甲状腺癌易感性及临床病理特征之间的关联强度。
本荟萃分析纳入了46项研究，共1700名对照和2298例甲状腺癌患者。合并结果表明，E-钙黏蛋白表达与乳头状癌和滤泡状癌的易感性显著相关（乳头状癌，OR = 14.31，95%CI = 3.42 - 59.90；滤泡状癌，OR = 10.14，95%CI = 4.52 - 22.75）。在基于对照组的亚组分析中，也观察到E-钙黏蛋白表达与甲状腺癌风险之间存在显著关联（正常甲状腺组织，OR = 28.28，95%CI = 8.36 - 95.63；甲状腺旁组织，OR = 8.83，95%CI = 3.27 - 23.85；良性甲状腺组织，OR = 43.96，95%CI = 9.91 - 194.95）。此外，E-钙黏蛋白表达与甲状腺癌的淋巴结转移、分化程度及肿瘤-淋巴结-转移（TNM）分期显著相关（淋巴结转移，OR = 3.21，95%CI = 1.98 - 5.20；分化程度，OR = 0.25，95%CI = 0.07 - 0.82；TNM分期，OR = 4.85，95%CI = 2.86 - 8.25）。
本研究表明，E-钙黏蛋白表达与甲状腺癌的易感性及临床病理特征显著相关，提示E-钙黏蛋白表达可能是甲状腺癌临床进展的潜在预测因素。
